Lifestyle program tested for remission of type 2 diabetes in primary care
Tests a lifestyle program on adults with type 2 diabetes treated in primary care.
Plain-language title generated from the registry record
Registry title: Lifestyle Intervention for Type 2 Diabetes in Primary Care (CREDOenAP)
Key facts
- Where
- Barcelona, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07207980, who can take part
Where in Spain
- Parc Sanitari Pere VirgiliBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Parc Sanitari Pere Virgili
- Trial code
- NCT07207980
- Record updated
- 6 October 2025
- Original description
The purpose of this clinical trial is to determine whether an intensive lifestyle intervention can achieve remission of type 2 diabetes mellitus (T2DM) in adult patients treated in primary care. The main questions the study seeks to answer are:Read full original descriptionShow less
Lifestyle Intervention Clinical Trial for the Remission of Type 2 Diabetes Mellitus in Primary Care (CREDOenAP)
The purpose of this clinical trial is to determine whether an intensive lifestyle intervention can achieve remission of type 2 diabetes mellitus (T2DM) in adult patients treated in primary care. The main questions the study seeks to answer are:
* What proportion of participants achieve diabetes remission after 6 months of intervention? * How many participants maintain remission 12 months after completing the program (18 months total)?
Participants will:
* Follow a personalized dietary plan with carbohydrate restriction. * Engage in moderate, accessible physical activity. * Implement strategies to improve circadian rhythm regularity. * Receive psychological counseling and support.
Inclusion: Signed informed consent; Men and women aged 18-80 years, inclusive; Confirmed diagnosis of T2DM according to recognized diagnostic criteria; Most recent recorded hemoglobin A1c (HbA1c) > 6.5%; Body Mass Index (BMI) greater than 27 kg/m².
Exclusion: Presence of serious or terminal comorbidities significantly worsening short- to medium-term prognosis (active cancer, terminal chronic diseases, myocardial infarction within the last 6 months, acute heart failure or NYHA stage ≥ III, etc.); History of ketoacidosis; Cognitive impairment; History of eating disorders; History of substance abuse; History of severe psychiatric disorders; Failure to meet the diagnostic criteria for T2DM in the screening laboratory tests; Presence of criteria or potential autoimmune insulinopenia (abnormal C-peptide, anti-GAD+ antibodies, pattern of basal and/or glucose-stimulated hypoinsulinemia); Being dependent for basic activities of daily living (Barthel score ≤ 90 points); Lack of willingness to cooperate with the follow-up of the lifestyle intervention plan; Weight loss exceeding 5 kg in the past 6 months; Significant changes in physical activity and/or dietary patterns in the past 6 months; Pregnancy or intention to become pregnant within the study period.